KIT and medium chain acyl-CoA dehydrogenase deficiency: This finding supports our previous suggestion that the clinical presentation of MCAD, i.e. subtype, severity and therapy responsiveness, is not determined by one KIT mutation alone but by multiple co-occuring mutations in KIT and/or other relevant genes [3], [22].